Stock Selection: Muse Spark 1.1's picks for 2026-11-03
Muse Spark 1.1 picked AMD, IDXX, SHOP, SUPN, LITE for a 1-day horizon. Portfolio return vs SPY: -3.31%. Picks that beat SPY: 40%.
| Experiment | Stock Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-11-03 |
| Measured to | 2026-11-04 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -3.31% |
| Picks that beat SPY | 40% |
| Benchmark return | +1.19% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | AMD | -1.26% | 68% | -2.45% | No |
| 2 | IDXX | +3.56% | 72% | +2.37% | Yes |
| 3 | SHOP | +4.62% | 61% | +3.43% | Yes |
| 4 | SUPN | -7.34% | 57% | -8.53% | No |
| 5 | LITE | -10.19% | 60% | -11.38% | No |
The model's market view
Nov 3 2026 is an earnings-driven session. Nov 2 after-close prints: AAPL beat $114.48B revenue and $2.10 EPS but margin outlook soft, IDXX beat $3.96 EPS vs $3.72 and $1.214B revenue +10% with raise, up 21.85%. Nov 2 $115B Marvell-Lumentum all-stock deal drove LITE -18.59% to $684.40 and MRVL -12.72% on 15.3M shares vs 7.7M average. Nov 3 before-open SHOP reported $3.74B +32% YoY vs $3.75B expected, EPS $0.49 vs $0.47 beat, but fell 8.3% intraday to $143.26 on GMV miss. SUPN began trading as combined Supernus-Indivior entity Nov 3, fell 28.46% to $29.99 despite Q3 revenue $226.8M vs $218.4M beat. AMD is scheduled after close Nov 3 with consensus $1.42, trading $489.10 up 4.77% intraday on $11.4B dollar volume ahead of print. SPY is soft on Apple margin guide. We favor names with clean, verified catalysts and volume 2-3x average, expecting bounce in oversold merger-related losers and continuation in earnings winners to outperform SPY over the next 24h window.
Why each pick
AMD
Thesis: Scheduled Q3 earnings after close Nov 3, confirmed Oct 6, call 5pm ET, is next catalyst inside window. Stock closed Nov 2 at $466.84 down 7.52% on 32M shares, then intraday Nov 3 open $479.99 high $497.40 low $473.54 close-trending $489.10 up 4.77% vs prior close on 11.4B daily dollar volume, indicating anticipation buying. Consensus $1.42 EPS, data center MI300 ramp and client CPU share gains expected to beat. Current quote is delayed regular-session price at time of answer, showing strength into print, and should outperform SPY if beat. Risks: high 128x P/E, 128% YTD run, guide risk on supply, beta 2.57 could reverse below $466.07 Nov 2 low on miss.
IDXX
Thesis: Q3 earnings Nov 2 8:30am ET beat EPS $3.96 vs $3.72 and revenue $1.214B vs $1.19B +10% with raised FY outlook. Stock gapped from $551.21 Oct 30 close to $671.64 Nov 2 close +21.85% on 1.97M shares vs 0.5M average and $343.75M dollar volume. Nov 3 intraday $667.73 down only 0.58% open $662.26 high $672.70 low $655.51 shows consolidation near high, not fade. Analyst target raises still incomplete midday Nov 3, leaving continuation room to outperform SPY. Clean catalyst, real revenue, $43.4B market cap, no offering. Risks: trading near 52-week high $769.98, valuation 38x, profit-taking after 17% 5-day move, healthcare multiple compression could cause reversal below $620.20 Nov 2 low.
SHOP
Thesis: Q3 before-open Nov 3 revenue $3.74B +32% YoY vs $3.75B expected (0.5% miss), adjusted EPS $0.49 vs $0.47 beat, operating income $568M +66%, FCF margin 22%. Stock opened $136.43 low $135.65 after 19% premarket drop, bounced to $143.2597 high $143.50 down 8.29% vs $156.22 prior close on 13.9M shares and $1.3B dollar volume. Move driven by GMV/subscription timing, not take rate, and is overdone vs operating leverage beat. Oversold bounce should outperform SPY next session as large-cap growth funds buy dip. $202.6B market cap, liquid. Risks: GMV $119B miss could signal consumer slowdown, beta 2.68 high, further de-risking into AMD earnings could press below $135.65 intraday low.
SUPN
Thesis: Q3 revenue $226.8M vs $218.4M estimate beat 3.9% +18.1% YoY, growth products +29%, raised standalone 2026 revenue outlook $875-900M, GAAP operating $21.2M vs -$60.2M loss YoY. Event coincides with start of trading as combined Supernus-Indivior entity Nov 3, stock fell from $41.92 prior close to $28.35 low then $29.99 down 28.46% on elevated volume $37.3M dollar volume, indicating technical supply from merger conversion, not fundamental miss. Rebound from capitulation wick low $28.35 to $31.20 intraday shows demand. Oversold bounce likely to outperform SPY. $2.44B market cap, real pharma revenue. Risks: integration costs, Indivior opioid liability overhang, small-cap volatility, failure to hold $28.35 low would signal continued selling.
LITE
Thesis: Definitive $115B all-stock acquisition by Marvell announced Nov 2, exchange 4.5 MRVL per LITE, deal value ~$771 at Monday close vs headline $1132 due to MRVL decline. LITE fell 18.59% Nov 2 to $684.40 on 15.3M shares vs 7.7M average and $3.86B dollar volume, then bounced Nov 3 to $689.11 open $685.00 high $691.00 low $679.00 up 0.69% intraday, indicating spread bottoming. Strategic logic creates combined 1.6T optical leader for AI data centers, 33% ownership to LITE holders, breakup protections support floor. Market has not priced long-term synergy; move is merger arbitrage not rumour or split. $76B market cap, high quality. Risks: fixed exchange ratio exposes to MRVL weakness, regulatory close mid-2028, beta 1.64 could amplify loss if market sells AI optics.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Claude Opus 5.5 | FISV, IDXX, HWM, RVTY, FN | -3.75% | 40% |
| Claude Sonnet 5.5 | OKTA, IDXX, FN, TEM, AMD | -3.70% | 20% |
| GPT-6 | FN, HWM, NXT, AMD, IDXX | -1.50% | 40% |
| GPT-6.1 Sol | IDXX, REGN, FN, HWM, NXT | -1.52% | 40% |
| Perplexity | IDXX, HWM, RIVN, PNR, SHW | +0.66% | 80% |
| Gemini 3 Pro | AEHR, FN, NBIX, RVTY, LSCC | -7.06% | 0% |
| Grok 4.7 | IDXX, LSCC, NBIX, FN, RVTY | -4.97% | 20% |
| DeepSeek | UPWK, TEVA, AEHR, HLIT, ON | -4.82% | 0% |
Written up on ForecastNest Insights: Stock Selection: Muse Spark 1.1's picks for 2026-11-03.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.